Streetbeat News

IRON

Disc Medicine, Inc.

https://www.discmedicine.com

Industry

Biotechnology

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Wells Fargo has initiated coverage on Disc Medicine (NASDAQ:IRON) with an Overweight rating and set a price target of $75.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 12:53 pm

Wedbush analyst David Nierengarten has reiterated an Outperform rating on Disc Medicine (NASDAQ:IRON) and maintained a price target of $57.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 2:07 pm

Disc Medicine (NASDAQ:IRON) reported a Q2 EPS loss of $(1.03), beating the analyst estimate of $(1.11) by 7.21%. This represents a 39.19% increase in losses compared to $(0.74) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:39 pm

BMO Capital analyst Evan Seigerman has reiterated an Outperform rating on Disc Medicine (NASDAQ:IRON) and raised the price target from $50 to $70.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 1:15 pm

U.S. stocks traded mixed with the Dow Jones and S&P 500 falling, while the NASDAQ rose slightly. RH shares plunged 18% after mixed Q1 results. Disc Medicine, SRIVARU Holding, and FOXO Technologies saw significant gains, while QXO and Gain Therapeutics experienced sharp declines.

Portfolio Pulse from Avi Kapoor

June 14, 2024 | 7:36 pm

AMMO, Inc. (NASDAQ:POWW) shares fell over 19% despite reporting a profit and higher-than-expected sales for the fourth quarter. Other notable stock movements include significant gains for Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) and SRIVARU Holding Limited (NASDAQ:SVMH), and declines for QXO, Inc. (NASDAQ:QXO) and Nexalin Technology, Inc. (NASDAQ:NXL).

Portfolio Pulse from Avi Kapoor

June 14, 2024 | 6:13 pm

The article highlights significant intraday movements in health care stocks on Friday. Cyclerion Therapeutics, CNS Pharma, Longeveron, iSpecimen, Scinai Immunotherapeutics, and Disc Medicine saw notable gains, while Nexalin Technology, Kyverna Therapeutics, Gain Therapeutics, IN8bio, Nanoviricides, and Rezolute experienced significant declines.

Portfolio Pulse from Benzinga Insights

June 14, 2024 | 4:31 pm

U.S. stocks traded lower with the Dow Jones falling over 200 points. The University of Michigan consumer sentiment declined for the third consecutive month. Disc Medicine, Inc. (NASDAQ:IRON) shares rose 20% after announcing a $178 million underwritten offering. SRIVARU Holding Limited (NASDAQ:SVMH) surged 120% on news of accepting reservations for its PRANA 2.0 product. FOXO Technologies Inc. (NASDAQ:FOXO) gained 16% after entering share exchange agreements. QXO, Inc. (NASDAQ:QXO) dropped 32% following a $3.5 billion private placement. IN8bio, Inc. (NASDAQ:INAB) fell 30% after presenting Phase 1 trial data. Gain Therapeutics, Inc. (NASDAQ:GANX) declined 33% after announcing an $11 million public offering.

Portfolio Pulse from Avi Kapoor

June 14, 2024 | 4:03 pm

Disc Medicine shares are trading higher following the announcement of data presentation at the European Hematology Association 2024 Congress and an underwritten offering.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 3:35 pm

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Disc Medicine (NASDAQ:IRON) and maintained a $70 price target.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 3:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.